Medivir's Licensee Tango Therapeutics Halts TNG348 Program

Medivir AB, a pharmaceutical company specializing in innovative cancer treatments, announced that its licensee, Tango Therapeutics, has decided to terminate the phase 1/2 clinical trial for TNG348, a novel USP1 inhibitor, due to toxicity concerns observed in early study participants. TNG348 was being investigated for its efficacy in treating BRCA1/2-mutant and other homologous recombination deficiency (HRD)+ cancers. Tango Therapeutics had developed TNG348 based on a preclinical USP1 program licensed from Medivir in 2020.

Despite this setback, Medivir remains committed to its primary focus and is actively advancing the development of its leading program, fostroxacitabine bralpamide (fostrox), aimed at treating primary liver cancer (HCC). The company is expediting several key initiatives to prepare for a pivotal phase 2b study with the aim of accelerated approval. Should the planned study yield positive results, fostrox has the potential to be the first approved treatment for HCC patients who have exhausted current first-line standard care options. The market for effective HCC treatments is projected to be valued at approximately $2.5 billion annually by 2028.

Medivir has emphasized that Tango Therapeutics' decision regarding TNG348 does not affect its ongoing efforts with fostrox. The company is leveraging the momentum of its fostrox development program, confident in its potential to address the significant unmet medical needs in liver cancer treatment. Medivir's focus is on developing innovative drugs in cancer therapy, particularly where there are limited or no existing treatment options, offering significant potential improvements for patients.

Founded on a model that values collaborations and partnerships, Medivir conducts drug development either independently or in collaboration with other entities. The company's shares are listed on Nasdaq Stockholm's Small Cap list, under the ticker MVIR.

Medivir is dedicated to creating smart, targeted chemotherapy treatments like fostrox that selectively treat cancer cells while minimizing side effects. This focused approach aims to offer significant benefits over existing therapies, particularly in areas with high unmet medical needs.

For any further information, Medivir directs inquiries to Magnus Christensen, the company’s CFO, who can be reached via telephone or email.

Medivir's commitment to cancer treatment innovation continues to drive their development programs, ensuring that they remain at the forefront of providing new and effective treatment options for patients facing serious and challenging cancers.